Skip to main content
Figure 5 | Breast Cancer Research

Figure 5

From: Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen

Figure 5

Relationship between estrogen receptor, HMG-CoAR and tamoxifen response in premenopausal breast cancer. (a) Kaplan-Meier estimate of recurrence-free survival based on tamoxifen treatment in estrogen receptor (ER)-positive and 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR)-positive tumors (n = 141). (b) Kaplan-Meier estimate of recurrence-free survival based on tamoxifen treatment in ER-positive or HMG-CoAR-positive tumors (n = 236). (c) Kaplan-Meier estimate of recurrence-free survival based on tamoxifen treatment in ER-negative and HMG-CoAR-negative tumors (n = 80). (d) Kaplan-Meier estimate of recurrence-free survival in tamoxifen-treated ER-positive patients based on HMG-CoAR expression. (e) Kaplan-Meier estimate of recurrence-free survival in untreated ER-positive patients based on HMG-CoAR expression. HR, hazard ratio.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us